TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2845043
Drug: DMSA 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMSA 350 mg/m2/day
Study: 2845043
Drug: DMSA 700
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMSA 700 mg/m2/day
Study: 2845043
Drug: DMSA 1050
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMSA 1050 mg/m2/day
Study: 2845043
Drug: CaNa2EDTA 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaNa2EDTA 1000 mg/m2/day
Study: 31415213
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of vitamin D3 (0.3 ml, 100,000 IU (2.5 mg/ml))
Study: 31415213
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of 2% zinc sulfate
Study: 31823141
Drug: MTX-hold group
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX-hold group (4-week discontinuation)
Study: 21433074
Drug: d‐chlorpheniramine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐chlorpheniramine 2 mg
Study: 19767812
Drug: Caffeine ingestion
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine ingestion (5 mg/kg fat-free mass; approximately 208-270 mg)
Study: 17530941
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (3.5 mg.kg(‐1) once weekly for 6 weeks)
Study: 17530941
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline injections once weekly for 6 weeks)
Study: 2258378
Drug: Sertraline (145
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (145 mg daily)
Study: 2258378
Drug: Amitriptyline (104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (104 mg daily)
Study: 6795614
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg cefuroxime i.m. with premedication and then 8 hourly for 3 days (group A)
Study: 6795614
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g cefuroxime i.v. at the time of induction of anaesthesia (group B)
Study: 6806060
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (group C)
Study: 27986838
Drug: Cornstarch-based gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cornstarch-based gel
Study: 29328522
Drug: Commercial gel
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial gel
Study: 23910063
Drug: Risperidone 2
Normalized name: risperidone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 2 mg orally before ERCP
Study: 15603203
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of pure histamine (equaling 124 mg histamine dihydrochloride, dissolved in peppermint tea)
Study: 22948897
Drug: Selegiline 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline 10 mg/day
Study: 27030562
Drug: Robotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic therapy using the Multi Joint System (MJS) device for 40 min, 5 days/week for 3 weeks, in addition to standard therapeutic physical exercises, massage, laser and pulsed current therapy.
Study: 27030562
Drug: Standard therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapeutic physical exercises, massage, laser and pulsed current therapy (control group).
Study: 25996101
Drug: Concurrent neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent neoadjuvant chemoradiotherapy (XELOX regimen)
Study: 23213070
Drug: Allopurinol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (100 mg or 300 mg)
Study: 21788967
Drug: Doxazosin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (4 mg) plus tolterodine SR (4 mg)
Study: 21788967
Drug: Doxazosin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (4 mg) plus placebo
Study: 19880460
Drug: STAR*D intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAR*D intervention (medication switching and augmentation)
Study: 16391588
Drug: alpha‐tocopherol 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐tocopherol 200 mg and ascorbic acid 100 mg twice daily
Study: 15349657
Drug: Single drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drug membrane
Study: 9279492
Drug: Cocaine Stimuli
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine Stimuli Condition (0.4 mg/kg delivery of cocaine)
Study: 9279492
Drug: Neutral Stimuli
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral Stimuli Condition (placebo, 5 mg)
Study: 8333814
Drug: Chlorthalidone, 25
Normalized name: Chlorthalidone, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone, 25 mg/d
Study: 8333814
Drug: Atenolol, 50
Normalized name: Atenolol, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol, 50 mg/d
Study: 2906255
Drug: Etintidine (E)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etintidine (E) HCl in capsules, ascending doses at 72‐h intervals
Study: 28790056
Drug: Aqueous chlorhexidine
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous chlorhexidine (0.5% chlorhexidine aqueous solution)
Study: 23743161
Drug: Yiqi Huaju
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqi Huaju Qingli formula treatment in combination with Western medicine
Study: 23743161
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with Western medicine
Study: 19859699
Drug: Glucose tablets
Normalized name: Glucose Tablets Orange Obsolete
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose tablets
Study: 1855729
Drug: Heparin-surface-modified PMMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-surface-modified PMMA IOL
Study: 7042110
Drug: Methylprednisolone (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (2.0 g i.v. on admission and 2.0 g i.v. 3 hours later)
Study: 31755803
Drug: Thyroxine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxine treatment (Group A)
Study: 31060544
Drug: Gastrectomy, CRS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrectomy, CRS and HIPEC after 3-4 cycles of systemic chemotherapy
Study: 31060544
Drug: Palliative systemic
Normalized name: Various pain palliation radiopharmaceuticals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative systemic chemotherapy only
Study: 28643618
Drug: Heat-stabilised rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-stabilised rice bran (30 g/d)
Study: 26056862
Drug: Oriental medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oriental medicine music therapy (OMMT)
Study: 18539337
Drug: Continuation phase
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation phase cognitive therapy (C‐CT) for 8 months
Study: 15510599
Drug: UDCA (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA (500 mg b.i.d)
Study: 9562365
Drug: CrH2O (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: CrH2O (4 x 5 g of CrH2O and 1 g glucose/day)
Study: 8504634
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 x 6 g of glucose/day)
Study: 23014081
Drug: Band and
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Band and loop (B&L) space maintainers
Study: 25788173
Drug: Crown and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crown and loop (C&L) space maintainers
Study: 18652323
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with inductance coupling treatment
Study: 16827023
Drug: Onlay with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onlay with buccal and palatal cuspal coverage
Study: 30146141
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) with homework completion after Sessions 2 and 3
Study: 30146141
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) with homework completion after Sessions 8 and 9
Study: 30146141
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) in the second half of treatment
Study: 22761409
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring (TDM) of voriconazole
Study: 22761409
Drug: Non-therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-therapeutic drug monitoring (non-TDM) of voriconazole
Study: 18703472
Drug: Tibolone (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (1.25 mg once daily)
Study: 2234856
Drug: Heparin surface-modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin surface-modified (HSM) lenses
Study: 197800
Drug: Dexamethasone (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (single oral dose)
Study: 197800
Drug: Desoxycorticosterone (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desoxycorticosterone (single oral dose)
Study: 197800
Drug: ACTH (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH (two i.v. injections of 60 IU each, at a 6-hour interval)
Study: 26247327
Drug: Therapist-aided exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-aided exposure treatment for 3 months
Study: 14535875
Drug: RBCAT (ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBCAT (ranitidine bismuth citrate 400 mg b.d. plus amoxicillin 1 g b.d. and tinidazole 500 mg b.d.)
Study: 14535875
Drug: PAL (pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAL (pantoprazole 40 mg b.d. plus amoxicillin 1 g b.d. and levofloxacin 500 mg/day)
Study: 14535875
Drug: PBTM (pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBTM (pantoprazole 40 mg b.d., bismuth citrate 240 mg b.d., tetracycline 500 mg q.d.s. and metronidazole 500 mg b.d.)
Study: 3294020
Drug: bepridil 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: bepridil 900 mg followed by 300 mg daily for 11 days
Study: 1603890
Drug: Triazolam 0.25
Normalized name: triazolam 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.25 mg (active drug)
Study: 373778
Drug: Secretolytic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secretolytic drugs
Study: 28350328
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (50,000 IU of oral VitD3 once weekly for 8 weeks)
Study: 19441980
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B 0.7 mg/kg plus fluconazole 800 mg
Study: 19441980
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B 0.7 mg/kg plus fluconazole 400 mg
Study: 19441980
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B 0.7 mg/kg (standard therapy)
Study: 9827927
Drug: Karnofsky index
Approvals — FDA: no, EMA: no, PMDA: no
Description: Karnofsky index > 60 and albuminaemia > or = 34 g/l
Study: 9827927
Drug: Karnofsky index
Approvals — FDA: no, EMA: no, PMDA: no
Description: Karnofsky index < or = 60 and albuminaemia < 34 g/l
Study: 8015506
Drug: Klimaxil (17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Klimaxil (17 beta‐estradiol 2 mg and medroxy‐progesterone acetate 5 mg)
Study: 8015506
Drug: Divina (17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divina (17 beta‐estradiol valerate 2 mg and medroxyprogesterone acetate 10 mg)
Study: 8015506
Drug: Trisequence (17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trisequence (17 beta‐estradiol 2 mg in the first phase) and Provera (medroxyprogesterone acetate 5 mg)
Study: 25311593
Drug: Daclatasvir 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir 12 weeks (60 mg once daily) + peginterferon alfa-2a + ribavirin
Study: 25311593
Drug: Daclatasvir 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir 16 weeks (60 mg once daily) + peginterferon alfa-2a + ribavirin
Study: 21632064
Drug: St. John's
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John's Wort (810 mg/day)
Study: 16876451
Drug: Orange juice
Normalized name: Orange juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange juice and 0.5 g MCT per kg lean body mass
Study: 15702625
Drug: ACE inhibitors,
Normalized name: ACE INHIBITORS, PLAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors, CCBs, and conventional treatment (diuretics/beta-blockers)
Study: 10423078
Drug: Blood pressure
Normalized name: Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure lowering treatments
Study: 15702625
Drug: Regimens based
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimens based on different drug classes
Study: 25889313
Drug: Octreotide (OCT)
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide (OCT) 0.3 mg/day for 3 days
Study: 25889313
Drug: Scopolamine butylbromide
Normalized name: Scopolamine butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine butylbromide (SB) 60 mg/day for 3 days
Study: 10687323
Drug: Less parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less parenteral hydration
Study: 10687323
Drug: Pain relief
Normalized name: Pain Relief
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain relief treatment
Study: 1363053
Drug: Bupivacaine (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (high concentration, 5 mg/ml; low concentration, 2.5 mg/ml) with volumes of 15-20 ml (high) or 5-10 ml (low) injected at C6 or C7
Study: 1363053
Drug: Injection toward
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection toward C7 instead of C6
Study: 3887553
Drug: Pirenzepine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (50 mg twice daily)
Study: 30878612
Drug: Cupping treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cupping treatment
Study: 21559322
Drug: Benzodiazepine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine treatment
Study: 26637993
Drug: Cardiovascular seven‐faceted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiovascular seven‐faceted screening examinations including low‐dose non‐contrast CT scan, brachial and ankle blood pressure index, telemetric assessment of heart rhythm, cholesterol and plasma glucose measurement.
Study: 20878375
Drug: Bilateral superficial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral superficial cervical plexus block (SCPB) with 20 mL of a 1:1 mixture of 0.5% bupivacaine and 2% lidocaine
Study: 20878375
Drug: Morphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.1 mg·kg⁻¹ iv after dural closure
Study: 16647354
Drug: Standard drain
Normalized name: Standard Drainable Pouch One Piece
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drain removal (< 30 mL drainage in 24 hours or postoperative day 14)
Study: 10372699
Drug: GnRHa treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa treatment only (Group A)
Study: 1679252
Drug: Alternative somatic
Normalized name: Bos taurus somatic nerve preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative somatic treatments for schizophrenia
Study: 7237025
Drug: DDAVP (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP (1 deamino‐8‐D‐arginine vasopressin) at a dose of 1 microgram
Study: 7237025
Drug: DDAVP (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP (1 deamino‐8‐D‐arginine vasopressin) at a minimum effective dose of 2 ng/kg
Study: 30784208
Drug: PF‐04895162 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐04895162 (300 mg twice daily for 2 weeks)
Study: 28106903
Drug: Rd continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rd continuous (lenalidomide plus low-dose dexamethasone)
Study: 28106903
Drug: Rd18 (lenalidomide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rd18 (lenalidomide plus low-dose dexamethasone for 18 cycles)
Study: 24297841
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg racemic ketamine (Keta‐Race)
Study: 24297841
Drug: 9 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg/kg S‐ketamine (S‐Keta)
Study: 12607287
Drug: Fluvoxamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine treatment for 12 weeks
Study: 12607287
Drug: Fluvoxamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine treatment for 6 weeks
Study: 10691121
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (dosage adjusted on clinical grounds)
Study: 22378321
Drug: Intraoperative intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative intravenous and postoperative oral clindamycin for 7 days
Study: 10598660
Drug: CI-980 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-980 at 3.5 mg/m2/day for 3 days (continuous intravenous infusion)
Study: 10598660
Drug: CI-980 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-980 at 4.2 mg/m2/day with G-CSF (for brain tumor patients)
Study: 10598660
Drug: CI-980 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-980 at 5 mg/m2/day with G-CSF (for solid tumor patients)
Study: 10598660
Drug: CI-980 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-980 at 5 mg/m2/day regimen
Study: 1425821
Drug: Bromocriptine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine monotherapy (Group 1)
Study: 1425821
Drug: Early combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early combination of bromocriptine and levodopa (Group 2A)
Study: 30021625
Drug: Remifentanil 2
Normalized name: remifentanil 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 2 ng/mL (group R2)
Study: 30021625
Drug: Remifentanil 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 4 ng/mL (group R4)
Study: 30021625
Drug: Remifentanil 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 6 ng/mL (group R6)
Study: 18586813
Drug: Interdisciplinary programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdisciplinary programme (physiotherapy, occupational therapy, physical education)
Study: 11805349
Drug: L‐adrenaline (0.1ml/kg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐adrenaline (0.1ml/kg/dose in 1 in 10,000 solution)
Study: 11805349
Drug: Salbutamol (0.1mg/kg/dose)
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol (0.1mg/kg/dose)
Study: 8749227
Drug: Methylcobalamin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcobalamin + Steroid
Study: 19942723
Drug: Steroid
Normalized name: Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid
Study: 1386825
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil containing eicosapentaenoic acid (4.1 g/day) and docosahexaenoic acid (3.6 g/day)
Study: 6837242
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution and glucose
Study: 30644740
Drug: Citrus sinensis
Normalized name: CITRUS SINENSIS LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrus sinensis cv. 'Cara Cara' orange juice (500 mL daily)
Study: 30644740
Drug: Citrus sinensis
Normalized name: CITRUS SINENSIS LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrus sinensis cv. 'Bahia' orange juice (500 mL daily)
Study: 29336387
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 mcg/kg loading dose over 15 minutes, followed by 0.5 mcg/kg/h maintenance infusion for 2 hours)
Study: 22344576
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg every 4 weeks plus MTX
Study: 17957910
Drug: Pueraria mirifica
Normalized name: PUERARIA MIRIFICA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pueraria mirifica (PM) 50 mg daily, Group A
Study: 17957910
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE) 0.625 mg daily with/without medroxyprogesterone acetate (MPA) 2.5 mg, Group B
Study: 16360062
Drug: Sequential cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential cardiac resynchronization therapy (CRT) for six months
Study: 16360062
Drug: Sequential cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential cardiac resynchronization therapy (CRT)
Study: 16360062
Drug: Simultaneous cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous cardiac resynchronization therapy (CRT)
Study: 12463580
Drug: Neuraxial anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuraxial anesthesia with selective factor Xa inhibitor fondaparinux
Study: 2338698
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg per day (n = 17)
Study: 2338698
Drug: Nitrendipine 20
Normalized name: nitrendipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 20 mg daily (n = 18)
Study: 14658
Drug: Flunitrazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (1 mg and 2 mg)
Study: 31136460
Drug: Strict posturing
Normalized name: Euphrasia stricta extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict posturing and bilateral patching overnight (Treatment A)